|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.004 AUD | 0.00% |
|
0.00% | +14.29% |
| Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
| Mar. 14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
Avecho Biotechnology Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was AUD 0.758239 million compared to AUD 0.265898 million a year ago. Net loss was AUD 0.777674 million compared to AUD 1.74 million a year ago.
Basic loss per share from continuing operations was AUD 0.0004 compared to AUD 0.001 a year ago. Diluted loss per share from continuing operations was AUD 0.0004 compared to AUD 0.001 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 8.27M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
AVECHO BIOTECHNOLOGY LIMITED 
